12/5
02:36 pm
kala
KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Low
Report
KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
12/4
10:45 am
kala
KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
High
Report
KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
12/3
04:31 pm
kala
KALA BIO (NASDAQ:KALA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
KALA BIO (NASDAQ:KALA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/1
07:00 am
kala
KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
High
Report
KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
11/27
02:49 pm
kala
KALA BIO (NASDAQ:KALA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
KALA BIO (NASDAQ:KALA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/21
02:02 pm
kala
KALA BIO (NASDAQ:KALA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
KALA BIO (NASDAQ:KALA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
9/30
12:08 pm
kala
KALA BIO (NASDAQ:KALA) was given a new $1.50 price target on by analysts at Mizuho.
High
Report
KALA BIO (NASDAQ:KALA) was given a new $1.50 price target on by analysts at Mizuho.
9/30
10:13 am
kala
KALA BIO (NASDAQ:KALA) was downgraded by analysts at Mizuho from an "outperform" rating to a "neutral" rating. They now have a $1.50 price target on the stock.
High
Report
KALA BIO (NASDAQ:KALA) was downgraded by analysts at Mizuho from an "outperform" rating to a "neutral" rating. They now have a $1.50 price target on the stock.
9/30
06:23 am
kala
KALA BIO (NASDAQ:KALA) was downgraded by analysts at Lifesci Capital from a "strong-buy" rating to a "hold" rating.
High
Report
KALA BIO (NASDAQ:KALA) was downgraded by analysts at Lifesci Capital from a "strong-buy" rating to a "hold" rating.